BreathSpec study
Start date:December 2018 End date:
April 2019 Co-ordinated by:
Julia Grahamslaw Main trial site:
Liverpool School of Tropical Medicine
A multicentre prospective, observational, longitudinal cohort study in adult patients with suspected upper or lower respiratory infection (URTI/LRTI) to identify a spectrum of biomarkers in exhaled breath to discriminate participants with bacterial RTI from participants without.
Identification of chemical biomarkers in exhaled breath that potentially discriminates participants with bacterial RTI from participants without.
Additional endpoints explored will be variations of the chemical spectrum from all participants using a portable GC-IMS device (Breathspec) stratified by confounding factors, such as (but not limited to) gender, age, antibiotic therapy and smoking status.
Local PI
Dr Matt Reed
Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine
Research Team
Fiona McCurrach
Senior Research Nurse
Julia Grahamslaw
Lead Research Nurse
Alison Williams
Senior Research Nurse
Clare Moceivei
Senior Research Nurse
Caroline Blackstock
AMU Senior Research Nurse
Sian Dalgleish
Senior Research Nurse
Dr Adam Lloyd
Honorary Research Fellow & Lecturer
Emma Nugent
Research Project Manager
More EMERGE Trials
DASH Trial
DASH is a randomised clinical trial investigating a treatment to reverse the effects of blood-thinning medications.
Evaluating the role of early CT Coronary Angiography on patients with suspected or confirmed Acute Coronary Syndrome.
RAPID-CTCA Trial
Evaluating the role of early CT Coronary Angiography
TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.